Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

DNX-2401: Phase II started

August 22, 2016 7:00 AM UTC

DNAtrix and Merck & Co. Inc. (NYSE:MRK, Kenilworth, N.J.) began the open-label, U.S. Phase II CAPTIVE/KEYNOTE-192 trial to evaluate a single intratumoral injection of DNX-2401 followed 7-9 days later...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article